Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia.

Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia. Haematologica. 2017 03; 102(3):519-528.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Drug Monitoring
Drug Resistance, Neoplasm
Female
Fusion Proteins, bcr-abl
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid, Acute
Male
Maximum Tolerated Dose
Middle Aged
Mutation
Protein Kinase Inhibitors
Quinolines
Treatment Outcome
Young Adult

authors with profiles

Richard A. Larson